Cargando…

Follow-Up of Surgical or Nonsurgical Patients with Pulmonary Cryptococcosis: A Real-World Study

BACKGROUND: Surgical and medical treatments are applied to pulmonary cryptococcosis (PC) in the real world, while the prognosis of different therapies is uncertain. This study investigated diagnosis, real-world therapy, follow-up outcomes, and prognosis factors, aiming to deepen our understanding of...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Herui, Ma, Yiming, Zeng, Zihang, Luo, Lijuan, Li, Tiao, Zeng, Huihui, Chen, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285854/
https://www.ncbi.nlm.nih.gov/pubmed/35844359
http://dx.doi.org/10.2147/IDR.S352966
_version_ 1784747877914902528
author Li, Herui
Ma, Yiming
Zeng, Zihang
Luo, Lijuan
Li, Tiao
Zeng, Huihui
Chen, Yan
author_facet Li, Herui
Ma, Yiming
Zeng, Zihang
Luo, Lijuan
Li, Tiao
Zeng, Huihui
Chen, Yan
author_sort Li, Herui
collection PubMed
description BACKGROUND: Surgical and medical treatments are applied to pulmonary cryptococcosis (PC) in the real world, while the prognosis of different therapies is uncertain. This study investigated diagnosis, real-world therapy, follow-up outcomes, and prognosis factors, aiming to deepen our understanding of PC. METHODS: Patients pathologically diagnosed with PC were retrospectively reviewed and followed up. Further comparisons and subgroup analyses were conducted in surgical and nonsurgical treatment individuals. Univariable and multivariable logistic regression methods were used to explore the risk factors associated with treatment failure. RESULTS: One hundred and sixty-three patients were included in this study, of whom 92 underwent surgical removal of VATS or open lung surgery (68 of them received postoperative antifungal treatment) and 71 got antifungal drugs only. Compared with nonsurgical patients, surgical patients were more immunocompetent (73 [79.3%] cases vs 33 [46.5%]), showed milder symptoms and more limited pulmonary lesions. Although they had instant treatment response owing to lesions resection, there is no significant advantage in the rate of treatment failure. Multivariable regression showed independent predictive factors associated with treatment failure were polymorphonuclear (PMN)>6.30*10(9)/L, albumin (Alb) <40g/L and antifungal dosage <400mg/d. Further analysis among patients with different immune statuses or symptoms demonstrated that sufficient antifungal dosage could reduce the rate of treatment failure. CONCLUSION: PC showed variable and nonspecific clinical features. PC patients with limited nodules/masses and mild symptoms often led to misdiagnosis and unnecessary lung resections. The potential risk factors including higher PMN and hypoalbuminemia could help clinicians to identify PC patients with poor treatment efficiency at an early stage. To note, sufficient antifungal dosage may improve the treatment outcomes.
format Online
Article
Text
id pubmed-9285854
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-92858542022-07-16 Follow-Up of Surgical or Nonsurgical Patients with Pulmonary Cryptococcosis: A Real-World Study Li, Herui Ma, Yiming Zeng, Zihang Luo, Lijuan Li, Tiao Zeng, Huihui Chen, Yan Infect Drug Resist Original Research BACKGROUND: Surgical and medical treatments are applied to pulmonary cryptococcosis (PC) in the real world, while the prognosis of different therapies is uncertain. This study investigated diagnosis, real-world therapy, follow-up outcomes, and prognosis factors, aiming to deepen our understanding of PC. METHODS: Patients pathologically diagnosed with PC were retrospectively reviewed and followed up. Further comparisons and subgroup analyses were conducted in surgical and nonsurgical treatment individuals. Univariable and multivariable logistic regression methods were used to explore the risk factors associated with treatment failure. RESULTS: One hundred and sixty-three patients were included in this study, of whom 92 underwent surgical removal of VATS or open lung surgery (68 of them received postoperative antifungal treatment) and 71 got antifungal drugs only. Compared with nonsurgical patients, surgical patients were more immunocompetent (73 [79.3%] cases vs 33 [46.5%]), showed milder symptoms and more limited pulmonary lesions. Although they had instant treatment response owing to lesions resection, there is no significant advantage in the rate of treatment failure. Multivariable regression showed independent predictive factors associated with treatment failure were polymorphonuclear (PMN)>6.30*10(9)/L, albumin (Alb) <40g/L and antifungal dosage <400mg/d. Further analysis among patients with different immune statuses or symptoms demonstrated that sufficient antifungal dosage could reduce the rate of treatment failure. CONCLUSION: PC showed variable and nonspecific clinical features. PC patients with limited nodules/masses and mild symptoms often led to misdiagnosis and unnecessary lung resections. The potential risk factors including higher PMN and hypoalbuminemia could help clinicians to identify PC patients with poor treatment efficiency at an early stage. To note, sufficient antifungal dosage may improve the treatment outcomes. Dove 2022-07-11 /pmc/articles/PMC9285854/ /pubmed/35844359 http://dx.doi.org/10.2147/IDR.S352966 Text en © 2022 Li et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Li, Herui
Ma, Yiming
Zeng, Zihang
Luo, Lijuan
Li, Tiao
Zeng, Huihui
Chen, Yan
Follow-Up of Surgical or Nonsurgical Patients with Pulmonary Cryptococcosis: A Real-World Study
title Follow-Up of Surgical or Nonsurgical Patients with Pulmonary Cryptococcosis: A Real-World Study
title_full Follow-Up of Surgical or Nonsurgical Patients with Pulmonary Cryptococcosis: A Real-World Study
title_fullStr Follow-Up of Surgical or Nonsurgical Patients with Pulmonary Cryptococcosis: A Real-World Study
title_full_unstemmed Follow-Up of Surgical or Nonsurgical Patients with Pulmonary Cryptococcosis: A Real-World Study
title_short Follow-Up of Surgical or Nonsurgical Patients with Pulmonary Cryptococcosis: A Real-World Study
title_sort follow-up of surgical or nonsurgical patients with pulmonary cryptococcosis: a real-world study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285854/
https://www.ncbi.nlm.nih.gov/pubmed/35844359
http://dx.doi.org/10.2147/IDR.S352966
work_keys_str_mv AT liherui followupofsurgicalornonsurgicalpatientswithpulmonarycryptococcosisarealworldstudy
AT mayiming followupofsurgicalornonsurgicalpatientswithpulmonarycryptococcosisarealworldstudy
AT zengzihang followupofsurgicalornonsurgicalpatientswithpulmonarycryptococcosisarealworldstudy
AT luolijuan followupofsurgicalornonsurgicalpatientswithpulmonarycryptococcosisarealworldstudy
AT litiao followupofsurgicalornonsurgicalpatientswithpulmonarycryptococcosisarealworldstudy
AT zenghuihui followupofsurgicalornonsurgicalpatientswithpulmonarycryptococcosisarealworldstudy
AT chenyan followupofsurgicalornonsurgicalpatientswithpulmonarycryptococcosisarealworldstudy